Marker Therapeutics (NASDAQ:MRKR) reported quarterly losses of $(0.09) per share which beat the analyst consensus estimate of $(0.47) by 81.68 percent. This is a 79.29 percent increase over losses of $(0.42) per share from the same period last year. The company reported quarterly sales of $1.103 million which beat the analyst consensus estimate of $723.000 thousand by 52.56 percent. This is a 51.02 percent decrease over sales of $2.252 million the same period last year.